Impact of Fluorinated Ionic Liquids on Human Phenylalanine Hydroxylase—A Potential Drug Delivery System

Márcia M. S. Alves 1,2, Paula Leandro 3, Haydyn D. T. Mertens 4,*, Ana B. Pereiro 2,*, and Margarida Archer 1,*

Abstract: Phenylketonuria (PKU) is an autosomal recessive disease caused by deficient activity of human phenylalanine hydroxylase (hPAH), which can lead to neurologic impairments in untreated patients. Although some therapies are already available for PKU, these are not without drawbacks. Enzyme-replacement therapy through the delivery of functional hPAH could be a promising strategy. In this work, biophysical methods were used to evaluate the potential of \([\text{N}_{1112}(\text{OH})\text{C}_4\text{F}_9\text{SO}_3]\), a biocompatible fluorinated ionic liquid (FIL), as a delivery system of hPAH. The results herein presented show that \([\text{N}_{1112}(\text{OH})\text{C}_4\text{F}_9\text{SO}_3]\) spontaneously forms micelles in a solution that can encapsulate hPAH. This FIL has no significant effect on the secondary structure of hPAH and is able to increase its enzymatic activity, despite the negative impact on protein thermostability. The influence of \([\text{N}_{1112}(\text{OH})\text{C}_4\text{F}_9\text{SO}_3]\) on the complex oligomerization equilibrium of hPAH was also assessed.

Keywords: fluorinated ionic liquids; surface-active ionic liquids; human phenylalanine hydroxylase; phenylketonuria; encapsulation

1. Introduction

Ionic Liquids (ILs) are salts comprised of an organic cation and inorganic anion, which present melting points close to 373.15 K. These molten salts present several physicochemical properties, such as viscosity, hydrophobicity, density, solubility, toxicity, and biodegradability, which can be easily tailored by modifying the functional group, anion, or cation [1]. Their versatility and tuneability allow targeted chemical structure design for the desired application. Thus, ILs show significant potential in the pharmaceutical field as enhancers of drug solubility, permeation, and stability, and as reaction media for organic and enzyme stabilization reactions, separations, and extractions [2–4]. ILs are also able to improve the stability and activity of proteins and enzymes [5,6]. Protein stability in ILs depends on the IL’s structure and composition, protein surface composition and charge, specific anion/cation effects, and the aqueous environment [6,7]. The structural diversity present in both ILs and proteins suggests multiple and complex solvent–protein interactions [7].

IL surface activity can be increased by lengthening the alkyl chain, yielding surface-active ionic liquids (SAILs) [8,9]. SAILs are environmentally friendly surfactants [10], whose hydrophobicity can be tailored by adjusting the length of the alkyl chain, the type of head group, and the counterion. Therefore, the resulting aggregates, such as micelles, can be finely tuned to have the desired structure and dynamics. Because of their...
ability to enhance drug permeability across biomembranes and to substitute conventional surfactants in drug carriers, SAILs are very desirable to the pharmaceutical industry for protein formulation and delivery [11–13]. Furthermore, SAILs can substitute surfactants in protein preparations with commercial applications such as in cosmetics, detergents, and biochemical reactions [14].

Fluorinated ionic liquids (FILs) are SAILs whose alkyl chain contains a fluorous tag comprised of four or more carbon atoms that self-assemble into distinct structures depending on their concentration in solution [15]. These FILs have been shown to be biocompatible and non-toxic in four human cell lines [16] and in aquatic species with different levels of organization [17]. Moreover, the effect of these FILs on model proteins—lysozyme and bovine serum albumin (BSA)—has been evaluated [18,19]. Further studies are needed with therapeutic proteins to gain insights into their interactions with FILs and assess the potential use of these FILs as protein drug carriers.

In this work, we have selected human phenylalanine hydroxylase (hPAH), a potentially therapeutic enzyme with a molecular mass around 210 kDa and a more complex structural and functional mechanism than the previously studied proteins [18,19]. hPAH is a member of the aromatic amino acid hydroxylase family and catalyzes the conversion of L-Phenylalanine (L-Phe) into L-Tyrosine (L-Tyr) in the liver using tetrahydrobiopterin (BH₄) and dioxygen as cofactors. Interestingly, besides being a substrate, L-Phe is also an allosteric regulator of hPAH. hPAH assembles as a tetramer (dimer of dimers) where each 52 kDa subunit contains three functional and structural domains: (1) the N-terminal regulatory domain; (2) the central catalytic domain, which contains the binding sites for substrate, iron, and cofactors (active site); and (3) the C-terminal oligomerization domain, which mediates the interaction between the two dimers [20–22]. Presently, ~1200 different mutations in the gene coding for hPAH (PAH) have been identified that can affect protein expression, folding, catalysis, or regulation and lead to phenylketonuria (PKU). PKU is characterized by an increase in the concentration of circulating L-Phe (hyperphenylalaninemia), leading, in the central nervous system, to high levels of L-Phe and low concentrations of L-Tyr and L-Trp, the precursors of amine neurotransmitters [23]. Due to L-Phe neurotoxicity and neurotransmitters depletion, untreated patients may present severe psycho-motor delays [24]. The current treatments for PKU include lifelong dietary restrictions of L-Phe sources (dietetic approach) and pharmacological therapies such as supplementation with BH₄ (acting as a pharmacological chaperone) and enzyme substitution therapy with a pegylated form of the non-human enzyme phenylalanine ammonia lyase (PEG-PAL) [21,22,25]. Nevertheless, disadvantages have been described for all the available therapies [23]. The diet is problematic, unpalatable, and needs to be maintained through life, and thus non-compliance during adolescence and adulthood is a common cause of progressive neurodegeneration. Cofactor supplementation is limited to patients carrying BH₄-responsive genotypes, usually associated with mild PAH missense mutations, and immunogenic events have been described in patients undergoing PEG-PAL therapy. Delivery of functional hPAH (enzyme reposition therapy) to patients suffering from PKU would be an alternative and “universal” strategy to treat this disease, covering the full spectrum of PAH genotypes and avoiding the immunogenicity associated with the administration of a non-human enzyme.

Herein, we studied the interaction between hPAH and a biocompatible, choline-based SAIL, [N₁₁₂(OH)][C₄F₉SO₃], so proof of concept can be established to further develop a novel drug delivery system. Biophysical techniques have been used to assess the impact of this surfactant’s IL on the activity, stability, and structure of hPAH, such as nano differential scanning fluorimetry (DSF), limited proteolysis, circular dichroism (CD), and small-angle X-ray scattering (SAXS). Furthermore, transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used to evaluate protein encapsulation. This work aims to determine whether hPAH remains active, maintaining the necessary preactivation by the substrate after encapsulation by non-toxic, biocompatible [N₁₁₂(OH)][C₄F₉SO₃], supporting its use for biomedical applications.
2. Materials and Methods

2.1. hPAH Production

Recombinant full-length hPAH was produced in *Escherichia coli* Top10 cells transformed with pTrcHis-hPAH expression construct. hPAH is produced as a fusion protein with an N-terminal His6-tag and a 26 amino acid linker [26]. Bacterial cells were grown in Luria–Bertani broth supplemented with 50 µg·mL⁻¹ ampicillin, at 310.15 K and 220 rpm with continuous shaking. When OD₆₀₀ was between 0.4 and 0.6, expression was induced by the addition of 1 mM isopropylthio-β-D-galactoside and 0.2 mM ferrous ammonium sulfate (Fe²⁺). After 3 h at 310.15 K, cells were harvested (3000 x g, 20 min, 277.15 K), and pellets were resuspended in Lysis Buffer (50 mM sodium phosphate pH 7.8, 300 mM NaCl, 1% glycerol) supplemented with 1 mM phenylmethylsulfonyl fluoride, DNaseI, and 1 mg·mL⁻¹ lysozyme. Cells were then disrupted by sonication (Branson Sonifier 450D, Fisher Scientific, Waltham, MA, USA) in three cycles of 60 s at 50% amplitude, and the soluble fraction was recovered after centrifugation (13,000 x g, 40 min, 277.15 K). The first purification step consisted of immobilized metal affinity chromatography. Ni-NTA resin (Qiagen GmbH, Hilden, Germany) was pre-equilibrated in lysis buffer supplemented with 10 mM imidazole, added to the cell lysate, and stirred for 1 h at 277.15 K. The resin was loaded onto a column and washed with increasing concentrations of imidazole (from 20 to 75 mM), and hPAH was eluted at 250 mM imidazole [27]. Size-exclusion chromatography (SEC) was performed using a Superdex 200 Increase 10/300 column (GE Healthcare, Chicago, IL, USA) in 20 mM HEPES pH 7.0, 200 mM NaCl (SEC buffer), at 277.15 K (see Figure S1 of Supplementary Materials (SM)). Isolated tetramers were flash-frozen and kept at 193.15 K until needed. All further assays were performed using SEC buffer unless otherwise stated.

2.2. Enzymatic Assays

The formation of L-Tyr by hPAH was measured as previously described in [28] using a final reaction volume of 200 µL. The reaction mix to follow the activity of hPAH in its preactivated condition was set up using 5 µg His₆-hPAH, 1 mM L-Phe, 0.1 mg·mL⁻¹ catalase, and 0–2% v/v cholinium perfluorobutanesulfonate, [N₁₁₁₂(OH)]\[C₄F₉SO₃\] (>97% mass fraction purity; Figure 1) supplied by IoLiTec GmbH, Heilbronn, Germany, and incubated for 4 min at 298.15 K. A total of 100 µM Ferrous (Fe²⁺) ammonium sulfate was added and further incubated for 1 min at 298.15 K. The reaction was initiated with 75 µM BH₄ and stopped after 1 min with the addition of 200 µL of cold 2% (v/v) acetic acid/ethanol solution. The reaction to study non-activated hPAH activity was set up similarly, but the substrate L-Phe (1 mM) was added simultaneously with BH₄. The amount of L-Tyr produced was quantified by HPLC using a Symmetry C18 (5 µm) column (Waters Corporation, Milford, MA, USA), a 10% ethanol mobile phase pumped at 1 mL·min⁻¹, and fluorimetric detection (λₑₓᶜₑ = 274 nm and λₑₘᵢₙ = 304 nm). Adequate controls were always performed to exclude the presence of possible interferents. Specific activities are presented as the mean ± standard deviation (SD) of triplicate experiments and expressed in nmol of L-Tyr produced during 1 min per mg of hPAH (nmol L-Tyr·min⁻¹·mg⁻¹).

![Chemical structure of cholinium perfluorobutanesulfonate, \([N_{1112}(OH)]\[C_4F_9SO_3]\).](attachment:Figure1.png)
2.3. Nano Differential Scanning Fluorimetry

Experiments of nanoDSF were performed on a Prometheus NT.48 instrument (NanoTemper Technologies GmbH, München, Germany). Protein intrinsic fluorescence was recorded at wavelengths (λ) of 330 and 350 nm as the temperature increased from 293.15 to 363.15 K at a rate of 1 K·min⁻¹. Samples of 0.25 mg·mL⁻¹ hPAH with increasing concentrations of FIL (from 0 to 2% v/v) and 1 mM L-Phe were loaded into Prometheus Capillaries (NanoTemper Technologies GmbH, München, Germany). Melting temperatures (T_m) were calculated from the minimum of the first derivative. The T_m values in the presence of [N_{1112}(OH)] [C_4F_9SO_3] were compared to those obtained in the absence of FIL to calculate ΔT_m. In addition, to monitor the effect of L-Phe on the stability of the regulatory and catalytic domains, T_m values in the presence of 1 mM L-Phe were compared with those obtained in its absence (ΔT_m-L-Phe) for each condition.

2.4. Limited Proteolysis

hPAH was incubated for 10 min at 298.15 K in the absence or presence of 0.6% v/v [N_{1112}(OH)] [C_4F_9SO_3] and/or L-Phe 1 mM. Trypsin was added at 1:200 mass ratio trypsin:hPAH at 298.15 K in SEC Buffer. At each time point, an aliquot was collected, and leupeptin (trypsin:leupeptin mass ratio of 1:1.5) was added to stop the reaction, followed by the addition of 4x loading buffer and sample denaturation at 368.15 K for 5 min. SDS-PAGE was used to assess the proteolytic profile. Samples were loaded into 4–12% Bis-Tris precast gels (Thermo Fisher Scientific, Waltham, MA, USA) and ran with 1× NuPAGE MES Running Buffer (Thermo Fisher Scientific, Waltham, MA, USA) at 190 V. Relative density of the bands was quantified with ImageJ 1.53e (NIH, Bethesda, MD, USA) [29] and fitted to a two-phase exponential decay equation using GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA).

2.5. Circular Dichroism

A JASCO J-815 spectropolarimeter (JASCO Inc., Tokyo, Japan) was used to record CD spectra at 293.15 K with a quartz cuvette of 0.1 cm path length. Samples were prepared in 20 mM Tris HCl, 50 mM KCl, pH 7.5, to avoid interference from HEPES buffer with measurements in the far-UV. Samples of hPAH at final concentration of 0.2 mg·mL⁻¹ were incubated with 0 to 2% v/v of [N_{1112}(OH)] [C_4F_9SO_3] for at least 10 min at room temperature. CD spectra were acquired from 190 to 260 nm at scan speeds of 50 nm·min⁻¹ with 5 accumulations and a response time of 1 s. Spectral deconvolution was carried out with Dichroweb, using the K2D algorithm [30–32].

2.6. Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE)

Samples containing hPAH and 0–1.2% v/v [N_{1112}(OH)] [C_4F_9SO_3] were prepared and analyzed using a blue native polyacrylamide gel electrophoresis-based system from Thermo Fisher Scientific (Waltham, MA, USA). The samples were loaded onto a NativePAGE 4–16% Bis-Tris gel with molecular weight marker NativeMark Unstained Protein Standard (Thermo Fisher Scientific, Waltham, MA, USA), and the electrophoresis was run according to manufacturer’s guidelines. Relative band density was analyzed using ImageJ software 1.53e (NIH, Bethesda, MD, USA) [29].

2.7. Small Angle X-ray Scattering

SAXS data were collected at beamline P12 operated by EMBL Hamburg at the PETRA III storage ring (DESY, Hamburg, Germany) [33]. Measurements were performed under constant flow in batch mode using a protein concentration of 0.9 mg·mL⁻¹ in SEC Buffer, containing 0–1.2% v/v [N_{1112}(OH)] [C_4F_9SO_3] and in the absence and presence of L-Phe (final concentration of 1 mM). Images were recorded using a Pilatus-6M detector at a sample to detector distance of 3.0 m and λ = 0.12 nm, covering the range of momentum transfer 0.01 < s < 7 nm⁻¹ (s = 4πsinθ/λ, where 2θ is the scattering angle). Data were processed and analyzed with the ATSAS program suite, version 3.0.3.1 (Hamburg, Germany) [34], using
PRIMUS [35] for further subtraction and averaging as required and for radius of gyration ($R_g$) and other SAXS invariant estimations. The program OLIGOMER [35] (from ATSAS suite) was used for equilibrium analysis of volume fractions of components in solution, with computed scattering intensities of components (PDB ID: 5FII and 2PAH) calculated in FFMAKER (from ATSAS suite) [35].

2.8. Dynamic Light Scattering

DLS measurements were performed on a Zetasizer Nano Series ZEN3600 (Malvern Instruments, Malvern, UK) apparatus equipped with a 633 nm laser using a non-invasive back-scattering technique (173°) for detection. A 10% v/v stock solution of $[\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]$ in MilliQ water was prepared and filtered prior to use (Milliporous PVDF filters, 0.22 µM), and hPAH was diluted to final concentration of 0.2 mg mL$^{-1}$. Samples were equilibrated for 30 min at room temperature prior to measuring. A 30 µL aliquot of each sample was loaded into a Hellma Quartz Cell QS 3.00 mm and measured 3 times. Cell temperature was kept constant at 298.15 K.

2.9. Transmission Electron Microscopy

Solutions containing 0.2 mg mL$^{-1}$ hPAH and 1.2% v/v $[\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]$ were pipetted on a 200 mesh copper grid (3 mm diameter) and left to air dry. Excess sample was then removed using filter paper. The grids were imaged at MicroLab-IST (Lisbon, Portugal) in a Hitachi 8100 model with LaB6 filament at a working voltage of 200 kV.

2.10. Statistical Analysis

Experimental data were analyzed with GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA) using one-way ANOVA followed by Dunnet test when appropriate. The differences were considered significant when $p < 0.0005$.

3. Results and Discussion

3.1. Stability and Function of hPAH

The activity of hPAH, which measures the conversion of L-Phe into L-Tyr after BH$_4$ addition, was $6095 \pm 372$ nmol Tyr min$^{-1}$·mg$^{-1}$ upon previous incubation with L-Phe and $1317 \pm 117$ nmol L-Tyr·min$^{-1}$·mg$^{-1}$ without L-Phe, corresponding to an increase of $4.6 \times$ upon L-Phe preactivation (Table 1). As L-Phe is both an allosteric activator and substrate of hPAH, the kinetic behavior of the enzyme depends on the order of addition of the reaction components, where pre-incubation with L-Phe yields higher rates of L-Tyr production [22,36].

Table 1. Catalytic activity of non-activated and preactivated hPAH in the absence and presence of increasing concentrations of $[\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]$. Data are shown as mean ± SD of triplicate assays. (*) Significant statistical differences.

| [N$_{1112}$(OH)][C$_4$F$_9$SO$_3$] (% v/v) | hPAH Activity (nmol Tyr min$^{-1}$·mg$^{-1}$) | L-Phe Activation Ratio |
|----------------------------------------|---------------------------------------------|------------------------|
|                                        | L-Phe Preactivation (1 mM L-Phe) | No L-Phe Preactivation |                          |
| 0                                      | 6095 ± 372 | 1317 ± 117 | 4.6 |
| 0.3                                    | 6643 ± 14  | 1643 ± 28 * | 4.0 |
| 0.6                                    | 6966 ± 60 * | 2075 ± 131 * | 3.4 |
| 1.2                                    | 6861 ± 339 * | 2178 ± 43 * | 3.2 |
| 2                                      | 6104 ± 298 | 2011 ± 176 * | 3.0 |

The presence of $[\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]$ at different concentrations, above and below its critical aggregation concentration (CAC) of 0.6% v/v [15], shows a growing positive impact in the enzymatic activity of hPAH (see Figure 2 and Table 1), followed by a slight decrease at 2% FIL. The addition of this FIL at 0.6–1.2% v/v increased the activity rates of
hPAH preactivated with L-Phe up to 13–14%, in contrast to 58–65% for the non-activated enzyme. This pronounced effect suggests that \([N_{1112}(OH)][C_4F_9SO_3]\) may preactivate hPAH to some extent in the absence of L-Phe, thus contributing to higher activity rates. As the concentration of \([N_{1112}(OH)][C_4F_9SO_3]\) increases, the L-Phe activation ratio decreases, mainly due to the higher hPAH activity in the basal state (non-preactivated).

![Relative activities of hPAH as a function of \([N_{1112}(OH)][C_4F_9SO_3]\) concentrations.](image)

**Figure 2.** Relative activities of hPAH as a function of \([N_{1112}(OH)][C_4F_9SO_3]\) concentrations. Relative enzymatic activity of non-activated and L-Phe activated hPAH. The activity of the hPAH in the absence of \([N_{1112}(OH)][C_4F_9SO_3]\) in the preactivated assay (1 mM L-Phe) was considered as 100%. Data are shown as mean ± SD of triplicate assays.

The thermal denaturation profile of hPAH, as monitored by nanoDSF, displays two transitions around 320 and 329 K, known to correspond to its regulatory \((T_m^1)\) and catalytic \((T_m^2)\) domains, respectively (see Figure 3 and Table 2). Pre-incubation with 1 mM L-Phe shifts these transitions to higher temperatures \((T_m^1 \sim 328 \text{ K}, T_m^2 \sim 331 \text{ K})\), thus showing a stabilizing effect \((\Delta T_m\text{L-Phe}: 7.5 \text{ and } 2 \text{ K, respectively})\), in agreement with previous reports [21,22].

![Thermotability of hPAH in the absence and presence of increasing concentrations of \([N_{1112}(OH)][C_4F_9SO_3]\).](image)

**Figure 3.** Thermotability of hPAH in the absence and presence of increasing concentrations of \([N_{1112}(OH)][C_4F_9SO_3]\). \(T_m\) values obtained from nanoDSF for hPAH (a) in the absence and (b) presence of 1 mM L-Phe. Data are shown as mean ± SD of triplicate assays.
The presence of L-Phe (1 mM) helps to smooth the protein's thermal destabilization of the regulatory domain by the FIL up to 0.6% (see Figure S2 of SM), after which ΔT_m increases to −18.99 and −24.34 K. The presence of L-Phe also smooths the decrease in T_m in the presence of FIL, as ΔT_m from −1.75 to −10.23 K were determined. However, when compared to the response of hPAH to L-Phe in the absence of FIL (ΔT_m L-Phe 7.5 K and ΔT_m L-Phe 2 K), higher ΔT_m L-Phe and ΔT_m2 L-Phe were observed for FIL concentrations of 0.3 and 0.6% (10.06 and 7.51 K) and 0.3–2% (4.82–3.85 K), respectively.

In the absence of L-Phe, [N1112(OH)][C₄F₉SO₃] destabilizes hPAH with a more significant effect on the catalytic domain. This destabilization may leave the catalytic domain more accessible to the substrate, leading to an increase in the activity rate of non-activated hPAH when compared to the control hPAH (0% FIL). The presence of FIL allows the protein to respond to the presence of L-Phe either at the functional and structural level, probably by an effect on the catalytic domain. Indeed, in the presence of different concentrations of FIL, the enzyme activity is 13–14% higher than the control value (6095 nmol Tyr·min⁻¹·mg⁻¹), correlating with the increase in the ΔT_m2 L-Phe observed for the tested concentrations.

hPAH limited proteolysis by trypsin was followed in the presence of 0.6% v/v FIL, since hPAH in the preactivated state showed higher enzymatic activity at this concentration (see Figure 2). The presence of [N1112(OH)][C₄F₉SO₃] resulted in a 6x slower digestion rate, as demonstrated in Figure 4 and Table 3 (for SDS-PAGE, see Figure S3 of SM). It has been described that decreased proteolytic rates can be due to higher protein compactness or to a lesser mobile protein conformation [22]. In addition, in the specific case of hPAH, higher resistance to proteolysis has also been associated with the movement of the regulatory domain, protecting the C-terminal region of this domain from trypsin digestion and leaving the catalytic domain more accessible to the substrate (high-activity state) [37], which seems to be the case when taking into consideration the activity and thermostability data. In addition, limited access of trypsin to the protein target sequences due to the presence of FIL may be excluded since the addition of L-Phe to the assay leads to a ~5× faster digestion rate. Under these conditions (1 mM L-Phe; 0.6% v/v of [N1112(OH)][C₄F₉SO₃]), the hPAH proteolytic profile approaches the profile obtained for hPAH without L-Phe and [N1112(OH)][C₄F₉SO₃], correlating with the similar T_m and T_m2 obtained for these conditions, namely 320.77 ± 0.02 and 329.53 ± 0.03 K (absence of L-Phe and [N1112(OH)][C₄F₉SO₃]) and 318.85 ± 0.07 and 328.23 ± 0.02 K (1 mM L-Phe: 0.6% v/v [N1112(OH)][C₄F₉SO₃]). These data may indicate similar conformational states.

Table 2. Variation of hPAH melting temperatures (T_m) measured by nanoDSF. ΔT_m - T_m variation in the presence of [N1112(OH)][C₄F₉SO₃] compared to those in its absence; ΔT_m L-Phe - T_m variation in the presence versus absence of 1 mM L-Phe.

| [N1112(OH)][C₄F₉SO₃] (% v/v) | ΔT_m (-L-Phe) | ΔT_m (+L-Phe) | ΔT_m L-Phe |
|-------------------------------|---------------|---------------|------------|
|                              | ΔT_m1         | ΔT_m2         | ΔT_m1      | ΔT_m2      |
| 0                            | -             | -             | -          | 7.5        | 2.0        |
| 0.3                          | -8.1          | -4.5          | -5.5       | -1.8       | 10.1       | 4.8        |
| 0.6                          | -9.4          | -6.0          | -9.4       | -3.3       | 7.5        | 4.7        |
| 1.2                          | -11.8         | -8.7          | -19.0      | -6.5       | 0.25       | 4.3        |
| 2                            | -15.8         | -12.0         | -24.3      | -10.2      | -1.1       | 3.8        |

The addition of [N1112(OH)][C₄F₉SO₃] to the protein has a detrimental effect on the thermostability of hPAH, which is more significant on the regulatory domain (ΔT_m1 from −8.1 to −15.8 K) than on the catalytic domain (ΔT_m2 from −4.53 to −12.04 K), as can be seen in Figure 3. The presence of L-Phe (1 mM) helps to smooth the protein's thermal destabilization of the regulatory domain by the FIL up to 0.6% (see Figure S2 of SM), after which ΔT_m increases to −18.99 and −24.34 K. The presence of L-Phe also smooths the decrease in T_m in the presence of FIL, as ΔT_m from −1.75 to −10.23 K were determined.
Tetramers are the predominant form, with some octamers present to a lesser extent (even)

Figure 4. Limited proteolysis of hPAH by trypsin. Degradation of full-length hPAH by trypsin, in the absence and presence of \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) and/or L-Phe.

Table 3. Effect of L-Phe on the proteolytic stability of hPAH in the presence and absence of \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) and L-Phe. Proteolytic rates \((k_{obs})\) were obtained from limited trypsin proteolysis.

| \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) (% v/v) | No L-Phe | 1 mM L-Phe |
|-----------------|----------|------------|
| 0               | 0.279    | 0.197      |
| 0.6             | 0.053    | 0.281      |

3.2. Effect of FIL on hPAH Structure

CD spectrum of hPAH presents two broad minima at 208 and 222 nm (see Figure 5), indicating \(\alpha\)-helices and \(\beta\)-sheets in its secondary structure [21]. The estimated 39% \(\alpha\)-helical content for hPAH (see Table 4) is in good agreement with previous reports [38]. Upon FIL addition, hPAH maintains its characteristic spectra with small variations in molar ellipticity, indicating that \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) does not affect the protein’s secondary structure.

Figure 5. Far-UV CD spectra of hPAH in the absence/presence of \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) from 0.3 to 2% v/v.

Therefore, the effects observed on the hPAH activity, thermostability, and proteolytic rate are not due to protein denaturation but may result from subtle changes in the tertiary structure of the protein in the presence of FIL. To analyze the impact of \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) on the quaternary structure of hPAH, blue native electrophoresis was performed (see Figure 6a), as it allows differentiation between the various oligomeric states of hPAH. Tetramers are the predominant form, with some octamers present to a lesser extent (even for the control assay; see Figure 6a, lane 2) as expected [36]. The addition of higher
concentrations of FIL (1.2%) leads to a slight increase in monomers, resulting from the
dissociation of octamers and tetramers (see Figure 6b). In the presence of L-Phe, a higher
level of octamers was found. However, the octameric form of hPAH is maintained, as
are the other oligomeric forms. Thus, \([N_{1112}(OH)][C_4F_9SO_3]\) (at 0.3 and 0.6% \(v/v\)) does not
influence the oligomeric state of non-activated and L-Phe activated hPAH, nor does it
promote the formation of aggregates with/without L-Phe.

Table 4. Estimation of secondary structure content of hPAH at different concentrations of
\([N_{1112}(OH)][C_4F_9SO_3]\).

| \([N_{1112}(OH)][C_4F_9SO_3]\) (% \(v/v\)) | \(\alpha\)-Helix | \(\beta\)-Sheet | Random coil |
|------------------------------------------|----------------|---------------|-------------|
| 0                                        | 0.39           | 0.09          | 0.52        |
| 0.3                                       | 0.40           | 0.14          | 0.46        |
| 0.6                                       | 0.38           | 0.08          | 0.54        |
| 1.2                                       | 0.40           | 0.11          | 0.49        |
| 2                                         | 0.38           | 0.07          | 0.55        |

Figure 6. Oligomerization states of hPAH. (a) Blue native electrophoresis. Gel 1 (reference): Lane
1—NativeMark; Lane 2—hPAH; Gel 2 (no L-Phe): Lane 3—hPAH, Lane 4—hPAH + 0.3% FIL;
Lane 5—hPAH + 0.6% FIL; Lane 6—hPAH + 1.2% FIL; Gel 3 (L-Phe): Lane 7—hPAH + L-Phe, Lane
8—hPAH + L-Phe + 0.3% FIL; Lane 9—hPAH + L-Phe + 0.6% FIL; Lane 10—hPAH + L-Phe + 1.2%
FIL. Relative quantification of (b) hPAH + FIL and of (c) hPAH + L-Phe + FIL calculated using ImageJ
software, considering, respectively, Lanes 3 and 7 as controls.
SAXS data were collected in order to assess possible \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) induced conformational changes in hPAH. The scattering curves are clearly different in the absence and presence of L-Phe, with the latter showing a broad peak at 0.12 Å\(^{-1}\) characteristic of a core–shell-like structure (Figure 7a). This reflects the L-Phe induced assembly of hPAH into a tetrameric and/or octameric structure. In the absence of L-Phe, this peak is absent, suggesting the sample is a polydisperse mixture of different assembly states (e.g., octamers, tetramers, and monomers). In the presence of FIL, the shift between hPAH’s resting (absence of L-Phe) and active state characteristic of domain assembly/rearrangement is maintained, confirming that \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) does not interfere with the mechanism of hPAH allosteric activation by L-Phe [22,28].

![Figure 7a](image1)

**Figure 7.** Effect of \([\text{N}_{1112}(\text{OH})][\text{C}_4\text{F}_9\text{SO}_3]\) on the SAXS profile of hPAH. (a) Experimental scattering curves of hPAH + FIL; (b) experimental scattering curves of hPAH + L-Phe + FIL; (c) volume fractions of oligomers in hPAH + FIL samples; (d) volume fractions of oligomers in hPAH + L-Phe + FIL samples.

In the absence of L-Phe, evidence of non-specific aggregate formation is observed at low angles, which increases with higher concentrations of FIL. In the presence of L-Phe, however, this behavior is only observed at FIL concentrations above 0.6% \(v/v\). Furthermore, an oligomerization analysis (see Figure 7b) of the scattering data, using the high-resolution domain structures of hPAH (PDB ID: 5FII, 2PAH) to define association/dissociation components, also suggests the presence of larger species, even before the addition of FIL. This effect has been reported in previous SAXS data collection of hPAH, where the protein tends to equilibrate between different oligomeric states [28,36]. SEC coupled to SAXS (SEC-SAXS) can usually overcome this; however, the interaction between ionic liquids and column matrices precluded the use of the SEC-SAXS mode in this case [39]. The oligomeric equilibrium analysis suggests that the SAXS data in the absence of L-Phe are best fit by a mixture...
of octameric, tetrameric, dimeric, and monomeric hPAH (Figure 7c,d). The concentration of dimeric hPAH is maintained, while the volume fraction of octameric hPAH decreases with increasing concentrations of [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}] accompanied by an increase in the monomer. For hPAH incubated with L-Phe, the octameric species is dominant, and the dimer is not selected. Interestingly, the ratio of oligomeric species is maintained across the FIL concentration series. These results are in agreement with the blue native electrophoresis described above, confirming that the addition of FIL at the tested concentrations does not influence the oligomerization of hPAH + L-Phe, while for the non-activated protein, a different oligomeric profile was only observed with 0.6% [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}].

Structural parameters such as radius of gyration (R\textsubscript{g}), Porod volume (V\textsubscript{P}), and approximated average molecular mass (MM), described in Table 5, are in agreement with published hPAH batch (i.e., non-SEC) measurements describing a mixture of oligomeric states [28]. These parameters tend to decrease with increasing FIL concentrations, indicating higher protein compactness on average or the dissociation of larger assemblies into tetrameric/dimeric and monomeric forms. For non-activated hPAH + 0.6% v/v FIL, for instance, the calculated MM is 77 kDa, which corresponds to the expected MM of monomeric hPAH [40], the most prevalent species in the sample (Figure 7c). Taking into consideration that octamers were the most prevalent forms for the preactivated hPAH in the presence of IL (Figure 7d) and that a decrease in all structural parameters was observed, the data seem to indicate higher protein compactness for those species as the [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}] concentration increases.

Table 5. SAXS structural parameters of hPAH in the presence and absence of [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}] and L-Phe. Radii of gyration (R\textsubscript{g}) were estimated from the Guinier approximation. Excluded particle volumes (V\textsubscript{P}) were estimated from the Porod approximation. Maximum particle dimensions (D\textsubscript{max}) were obtained from the pair-distribution function. Molecular mass (MM) values were derived from the Porod volume as MM = VP/1.6.

| [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}] (% v/v) | No L-Phe | 1 mM L-Phe |
|---------------------------------|--------|-----------|
|                                 | R\textsubscript{g} (Å) | V\textsubscript{P} (Å\textsuperscript{3}) | D\textsubscript{max} (Å) | MM (kDa) | R\textsubscript{g} (Å) | V\textsubscript{P} (Å\textsuperscript{3}) | D\textsubscript{max} (Å) | MM (kDa) |
| 0                               | 53.4 ± 1.1 | 459,446 | 168 | 287 | 61.7 ± 5.3 | 741,198 | 187 | 463 |
| 0.3                             | 50.4 ± 1.2 | 354,904 | 137 | 221 | 56.7 ± 2.9 | 617,827 | 164 | 386 |
| 0.6                             | 46.3 ± 1.8 | 122,885 | 117 | 77 | 58.7 ± 3.6 | 556,597 | 158 | 348 |
| 1.2                             | -        | -        | -   | -   | 58.9 ± 4.3 | 476,911 | 143 | 298 |

3.3. hPAH Encapsulation by FIL

In order to assess encapsulation of hPAH by [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}], both DLS and TEM were used to characterize and visualize micelles in solution. The DLS spectra showed a characteristic peak of hPAH at ~14 nm (see Figure 8a) [41], while the spectrum of 1.2% v/v [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}] (without hPAH) did not exhibit any aggregates in this range (see Figure 8b), with a bimodal distribution at higher diameter ranges (around 60 and 300 nm). The addition of 0.3% v/v FIL led to a decrease in the intensity of the protein peak, although it remains in the solution. At FIL concentrations above CAC (0.6–1.8% v/v), the protein peak completely disappears, and a single peak appears due to the strong interaction/association of FIL with hPAH, suggesting protein encapsulation. For example, hPAH + 1.2% [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}] exhibits only one broad peak with a mean size of ~600 nm (see Figure 8b). These results show a shift towards higher hydrodynamic diameters for [N\textsubscript{1112(OH)}][C\textsubscript{4}F\textsubscript{9}SO\textsubscript{3}] concentrations > 0.6% v/v, suggesting encapsulation of hPAH for FIL concentrations above CAC. Similar behavior has already been reported for lysozyme [18].
peak completely disappears, and a single peak appears due to the strong interaction/as-
sociation of FIL with hPAH, suggesting protein encapsulation. For example, hPAH + 1.2%
[N1112(OH)][C4F9SO3] exhibits only one broad peak with a mean size of ~600 nm (see Figure
8b). These results show a shift toward higher hydrodynamic diameters for [N1112(OH)][C4F9SO3]
concentrations > 0.6% v/v, suggesting encapsulation of hPAH for FIL concentrations above CAC.
Similar behavior has already been reported for lysozyme [18].

**Figure 8.** Encapsulation of hPAH by [N1112(OH)][C4F9SO3]. DLS spectra of hPAH upon: (a) the addition
of increasing concentrations of FIL; and (b) comparison between 1.2% v/v FIL Blank with hPAH + 1.2%
v/v FIL. (c) TEM analysis of 1.2% v/v FIL (top) and hPAH + 1.2% v/v FIL (bottom). Size
distribution (Feret diameter) of particles present in TEM images: (d) 1.2% v/v FIL and (e) hPAH + 1.2%
FIL v/v, quantified using ImageJ software.

TEM images were collected in the presence of 1.2% v/v [N1112(OH)][C4F9SO3], which
corresponds to 2 × CAC, to maximize the probability of protein encapsulation (see Figure
8c). Control samples (FIL, no hPAH) revealed the formation of heterogeneous micelles,
which also displayed a bimodal distribution of particle sizes of approximately 150 and
350 nm (see Figure 8d). This behavior and size distribution was previously observed for
similar FILs [18]. In the presence of hPAH, there was a clear increase in particle size to 500–600 nm (see Figure 8e). The sizes measured using the TEM micrographs are in accordance with the diameters obtained by DLS. Therefore, we conclude that, in the presence of hPAH, FIL aggregates become larger and more homogenous due to protein encapsulation. This encapsulation evidence observed by DLS and TEM is corroborated by SAXS. This experimental technique shows some evidence of those aggregates (e.g., upturns in the data at low angles). However, the Dmax of those large aggregates cannot be extracted because huge particles provide scattering intensities that are mostly intercepted by the beamstop. Furthermore, hPAH alone shows a DLS peak that matches reasonably with the SAXS (D$_{ \text{max} }$~17 nm), confirming the DLS data.

4. Conclusions

This study showed that the addition of [N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] at 0.6–1.2% v/v to hPAH increased the enzymatic activity in the absence or presence of L-Phe, despite decreasing protein thermostability (nanoDSF). The presence of FIL seems to confer hPAH some protection against trypsin digestion, so we postulate that [N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] may induce structural rearrangements on the N-terminal regulatory domain of hPAH, resulting in a more exposed catalytic domain, with higher basal activity (absence of L-Phe) but lower T$_{ \text{m} }$. Moreover, [N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] does not affect hPAH’s secondary structure (CD) nor its oligomerization states when the protein is pre-incubated with L-Phe; however, in the absence of L-Phe and at 1.2%, it favors the dissociation of octamers/tetramers into monomers (BN-PAGE). [N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] does not contribute to the aggregation of hPAH (BN-PAGE and SAXS). These are promising results as aggregates may lead to loss of function and immunogenic reactions, so this phenomenon should be prevented during protein formulation. In addition, incubation of hPAH with [N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] at concentrations ≥ 0.6% leads to the formation of larger molecular mass species ~1 µm (DLS), and the addition of hPAH to FIL self-assembled particles at 1.2% v/v also increases their sizes to similar values (TEM), thus suggesting protein encapsulation. Indeed, [N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] has high surface activity and has been previously shown to be able to form micelles and encapsulate lysozyme [15,18]. The results herein presented show that this FIL is still able to encapsulate a larger and more complex protein while still retaining its structure and function. Although [N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] has been found to be non-toxic in four human cell lines [16] and its eco-toxicity has also been assessed [17], studies on subjects such as the immunogenicity and delivery of this potential drug delivery system are needed to better understand hPAH-[N$_{1112}$(OH)]$_2$[C$_4$F$_9$SO$_3$] interactions.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nano12060893/s1, Figure S1: Size exclusion chromatography (SEC) profile of human phenylalanine hydroxylase (hPAH), Figure S2: Nano Differential Scanning Fluorimetry raw data, Figure S3: SDS-PAGE analysis of hPAH limited proteolysis.

Author Contributions: Conceptualization, M.M.S.A., P.L., A.B.P. and M.A.; validation, H.D.T.M. and P.L.; formal analysis, M.M.S.A. and H.D.T.M.; investigation, M.M.S.A. and H.D.T.M.; resources, H.D.T.M. and P.L.; writing—original draft preparation, M.M.S.A.; writing—review and editing, P.L., A.B.P. and M.A.; visualization, M.M.S.A.; supervision, P.L., A.B.P. and M.A.; project administration, M.A.; funding acquisition, A.B.P. and M.A. All authors have read and agreed to the published version of the manuscript.

Funding: This work was also supported by UID/QUI/50006/2020 (Associate Laboratory for Green Chemistry—LAQV), UIDB/04138/2020, and UIDP/04138/2020 (Research Institute for Medicines; iMed.Unlsoa) and MOSTMICRO–ITQB grants UIDB/04612/2020 and UIDP/04612/2020 financed by national funds from FCT/MCTES. MMSA acknowledges FCT for PD/BD/125201/2016 fellowship.

Acknowledgments: The synchrotron SAXS data was collected at beamline P12 operated by EMBL Hamburg at the PETRA III storage ring (DESY, Hamburg, Germany). We thank Catarina Tomé for the help with the SAXS interpretation and Lidia Gonçalves for fruitful discussions.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Adawiyah, N.; Moniruzzaman, M.; Hawatulaila, S.; Goto, M. Ionic liquids as a potential tool for drug delivery systems. *MedChemComm* 2016, 7, 1881–1897. [CrossRef]

2. Pedro, S.N.; Freire, C.S.R.; Silvestre, A.J.D.; Freire, M.G. The role of ionic liquids in the pharmaceutical field: An overview of relevant applications. *Int. J. Mol. Sci.* 2020, 21, 8298. [CrossRef] [PubMed]

3. de Almeida, T.S.; Júlio, A.; Saraiva, N.; Fernandes, A.S.; Araújo, M.E.M.; Baby, A.R.; Rosado, C.; Mota, J.P. Choline-versus imidazole-based ionic liquids as functional ingredients in topical delivery systems: Cytotoxicity, solubility, and skin permeation studies. *Drug Dev. Ind. Pharm.* 2017, 43, 1858–1865. [CrossRef] [PubMed]

4. Amaral, M.; Pereiro, A.B.; Gaspar, M.M.; Reis, C.P. Recent advances in ionic liquids and nanotechnology for drug delivery. *Nanomedicine* 2020, 16, 63–80. [CrossRef]

5. Reslan, M.; Kayser, V. Ionic liquids as biocompatible stabilizers of proteins. *Biophys. Rev.* 2018, 10, 781–793. [CrossRef]

6. Egorova, K.S.; Gordeev, E.G.; Ananikov, V.P. Biological Activity of Ionic Liquids and Their Application in Pharmaceutics and Medicine. *Chem. Rev.* 2017, 117, 7132–7189. [CrossRef]

7. Bui-Le, L.; Clarke, C.J.; Bröhl, A.; Brogan, A.P.S.; Arpino, J.A.J.; Polizzi, K.M.; Hallett, J.P. Revealing the complexity of ionic liquid–protein interactions through a multi-technique investigation. *Commun. Chem.* 2020, 3, 55. [CrossRef]

8. Pal, A.; Yadav, A. Binding interactions of anesthetic drug with surface active ionic liquid. *J. Mol. Liq.* 2016, 222, 471–479. [CrossRef]

9. Zhou, L.; Tian, T.; Xiao, J.; Wang, T.; Yu, L. Aggregation behavior of pyrrolidinium-based surface active ionic liquids in H2O-EAN binary solvents. *J. Mol. Liq.* 2017, 252, 50–55. [CrossRef]

10. Ali, M.K.; Moshikur, R.M.; Wakabayashi, R.; Tahara, Y.; Moniruzzaman, M.; Kamiya, N.; Goto, M. Synthesis and characterization of choline–fatty-acid-based ionic liquids: A new biocompatible surfactant. *J. Colloid Interface Sci.* 2019, 551, 72–80. [CrossRef]

11. Harada, L.; Pereira, J.; Campos, W.; Silva, E.; Moutinho, C.; Vila, M.; Oliveira, J., Jr.; Teixeira, J.; Balcão, V.; Tubino, M.; et al. Insights into Protein- Ionic Liquid Interactions Aiming at Macromolecule Delivery Systems. *J. Braz. Chem. Soc.* 2018, 29, 1983–1998. [CrossRef]

12. Singh, O.; Singla, P.; Aswal, V.K.; Mahajan, R.K. Aggregation and Morphological Aptitude of Drug-Based Ionic Liquids in Aqueous Solution. *ACS Omega* 2017, 2, 3296–3307. [CrossRef] [PubMed]

13. Singla, P.; Singh, O.; Chabba, S.; Mahajan, R.K. Pluronic-SAILs (surface active ionic liquids) mixed micelles as efficient hydrophobic quercetin drug carriers. *J. Mol. Liq.* 2018, 249, 294–303. [CrossRef]

14. Bharmor, P.; Kumar, A. Thermodynamic investigations of protein’s behaviour with ionic liquids in aqueous medium studied by isothermal titration calorimetry. *Biochim. Biophys. Acta-Gen. Subj.* 2016, 1860, 1017–1025. [CrossRef] [PubMed]

15. Pereiro, A.B.; Araújo, J.M.M.; Teixeira, F.S.; Marrucho, I.M.; Piñeiro, M.M.; Rebelo, L.P.N. Aggregation behavior and total miscibility of fluorinated ionic liquids in water. *Langmuir* 2015, 31, 1283–1295. [CrossRef] [PubMed]

16. Vieira, N.S.M.; Bastos, J.C.; Rebelo, L.P.N.; Matias, A.; Araújo, J.M.M.; Pereiro, A.B. Human cytotoxicity and octanol/water partition coefficients of fluorinated ionic liquids. *Chemosphere* 2019, 216, 576–586. [CrossRef] [PubMed]

17. Vieira, N.S.M.; Stolte, S.; Araújo, J.M.M.; Rebelo, L.P.N.; Pereiro, A.B.; Markiewicz, M. Acute Aquatic Toxicity and Biodegradability of Fluorinated Ionic Liquids. *ACS Sustain. Chem. Eng.* 2019, 7, 3733–3741. [CrossRef]

18. Alves, M.; Vieira, N.S.M.; Rebelo, L.P.N.; Araújo, J.M.M.; Pereiro, A.B.; Archer, M. Fluorinated ionic liquids for protein drug delivery systems: Investigating their impact on the structure and function of lysozyme. *Int. J. Pharm.* 2017, 526, 309–320. [CrossRef]

19. Alves, M.M.S.; Araújo, J.M.M.; Martins, I.C.; Pereiro, A.B.; Archer, M. Insights into the interaction of Bovine Serum Albumin with Surface-Active Ionic Liquids in aqueous solution. *J. Mol. Liq.* 2021, 322, 114537. [CrossRef]

20. Pey, A.L.; Thörölfssson, M.; Teigen, K.; Ugarte, M.; Martinez, A. Thermodynamic characterization of the binding of tetrahydropyridines to phenylalanine hydroxylase. *J. Am. Chem. Soc.* 2004, 126, 13670–13678. [CrossRef]

21. Cerreto, M.; Cavaliere, P.; Carluccio, C.; Amato, F.; Zagara, A.; Daniele, A.; Salvatore, F. Natural phenylalanine hydroxylase variants that confer a mild phenotype affect the enzyme’s conformational stability and oligomerization equilibrium. *Biochim. Biophys. Acta-Mol. Basis Dis.* 2011, 1812, 1435–1445. [CrossRef] [PubMed]

22. Tomé, C.S.; Lopes, R.R.; Sousa, P.M.F.; Amaro, M.P.; Leandro, J.; Mertens, H.D.T.; Leandro, P.; Vicente, J.B. Structure of full-length wild-type human phenylalanine hydroxylase by small angle X-ray scattering reveals substrate-induced conformational stability. *Sci. Rep.* 2019, 9, 13615. [CrossRef] [PubMed]

23. van Spronsen, F.J.; Blau, N.; Harding, C.; Burlina, A.; Longo, N.; Bosch, A.M. Phenylketonuria. *Nat. Rev. Dis. Prim.* 2021, 7, 36. [CrossRef]

24. Borges, A.C.; Broersen, K.; Leandro, P.; Fernandes, T.G. Engineering Organoids for in vitro Modeling of Phenylketonuria. *Front. Mol. Neurosci.* 2022, 14, 787242. [CrossRef] [PubMed]

25. Flydal, M.I.; Martinez, A. Critical Review Phenylalanine Hydroxylase: Function, Structure, and Regulation. *IUBMB Life* 2013, 65, 341–349. [CrossRef] [PubMed]

26. Leandro, P.; Rivera, I.; Lehner, M.C.; De Almeida, I.T.; Konecki, D. The V388M Mutation Results in a Kinetic Variant Form of Phenylalanine Hydroxylase. *Mol. Genet. Metab.* 2000, 69, 204–212. [CrossRef]

27. Montalbano, F.; Leandro, J.; Farias, G.D.V.F.; Lino, P.R.; Guedes, R.C.; Vicente, J.B.; Leandro, P.; Gois, P.M.P. Phenylalanine iminoboronates as new phenylalanine hydroxylase modulators. *RSC Adv.* 2014, 4, 61022–61027. [CrossRef]
28. Lopes, R.R.; Tomé, C.S.; Russo, R.; Paterna, R.; Leandro, J.; Candeias, N.R.; Gonçalves, L.M.D.; Teixeira, M.; Sousa, P.M.F.; Guedes, R.C.; et al. Modulation of human phenylalanine hydroxylase by 3-hydroxyquinolin-2(1H)-one derivatives. *Biomolecules* 2021, 11, 462. [CrossRef]

29. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to Image: 25 years of image analysis. *Nat. Methods* 2012, 9, 671–675. [CrossRef]

30. Whitmore, L.; Wallace, B.A. Protein secondary structure analyses from circular dichroism spectroscopy: Methods and reference databases. *Biopolymers* 2008, 89, 392–400. [CrossRef]

31. Andrade, M.A.; Chacón, P.; Merelo, J.J.; Morán, F. Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. *Protein Eng. Des. Sel.* 1993, 6, 383–390. [CrossRef] [PubMed]

32. Whitmore, L.; Wallace, B.A. DICROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. *Nucleic Acids Res.* 2004, 32, W668–W673. [CrossRef] [PubMed]

33. Blanchet, C.E.; Spilotros, A.; Schwemmer, F.; Graewert, M.A.; Kikhney, A.; Jeffries, C.M.; Franke, D.; Mark, D.; Zengerle, R.; Cipriani, F.; et al. Versatile sample environments and automation for biological solution X-ray scattering experiments at the P12 beamline (PETRA III, DESY). *J. Appl. Crystallogr.* 2015, 48, 431–443. [CrossRef] [PubMed]

34. Franke, D.; Petoukhov, M.V.; Konarev, P.V.; Panjkovich, A.; Tuukkanen, A.; Mertens, H.D.T.; Kikhney, A.G.; Hajizadeh, N.R.; Franklin, J.M.; Jeffries, C.M.; et al. ATSAS 2.8: A comprehensive data analysis suite for small-angle scattering from macromolecular solutions. *J. Appl. Crystallogr.* 2017, 50, 1212–1225. [CrossRef]

35. Konarev, P.V.; Volkov, V.V.; Sokolova, A.V.; Koch, M.H.J.; Svergun, D.I. PRIMUS: A Windows PC-based system for small-angle scattering data analysis. *J. Appl. Crystallogr.* 2003, 36, 1277–1282. [CrossRef]

36. Arturo, E.C.; Gupta, K.; Hansen, M.R.; Borne, E.; Jaffe, E.K. Biophysical characterization of full-length human phenylalanine hydroxylase provides a deeper understanding of its quaternary structure equilibrium. *J. Biol. Chem.* 2019, 294, 10131–10145. [CrossRef] [PubMed]

37. Jaffe, E.K.; Stith, L.; Lawrence, S.H.; Andrade, M.; Dunbrack, R.L. A new model for allosteric regulation of phenylalanine hydroxylase: Implications for disease and therapeutics. *Arch. Biochem. Biophys.* 2013, 530, 73–82. [CrossRef]

38. Miranda, F.F.; Teigen, K.; Thórholfsson, M.; Svebak, R.M.; Flatmark, T.; Martinez, A. Phosphorylation and mutations of Ser16 in human phenylalanine hydroxylase: Kinetic and structural effects. *J. Biol. Chem.* 2002, 277, 40937–40943. [CrossRef] [PubMed]

39. Huang, Y.; Yao, S.; Song, H. Application of ionic liquids in liquid chromatography and electrodriven separation. *J. Chromatogr. Sci.* 2013, 51, 739–752. [CrossRef]

40. Flydal, M.I.; Alcorlo-Pagès, M.; Johannessen, F.G.; Martínez-Caballero, S.; Skjærven, L.; Fernandez-Leiro, R.; Martínez, A.; Hermoso, J.A. Structure of full-length human phenylalanine hydroxylase in complex with tetrahydrobiopterin. *Proc. Natl. Acad. Sci. USA* 2019, 166, 11229–11234. [CrossRef]

41. Gersting, S.W.; Lagler, F.B.; Eichinger, A.; Kemter, K.F.; Danecka, M.K.; Messing, D.D.; Staudigl, M.; Domdey, K.A.; Zsifkovits, C.; Fingerhut, R.; et al. Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. *Hum. Mol. Genet.* 2010, 19, 2039–2049. [CrossRef] [PubMed]